Skip to main content

Guardian Pharmacy Services, Inc.

corporate_fare Company Profile

Guardian Pharmacy Services, Inc.

GRDN·NYSE·Life Sciences·CIK 0001802255

Guardian Pharmacy Services is a leading pharmacy services company providing technology-enabled services to residents of long-term care facilities (LTCFs). The company focuses on helping residents adhere to their drug regimens to reduce care costs and improve clinical outcomes. Guardian emphasizes individualized clinical, drug dispensing, and administration capabilities tailored for residents in historically lower acuity LTCFs, specifically assisted living facilities (ALFs) and behavioral health facilities and group homes (BHFs). Over two-thirds of Guardian's annual revenue for each of the past three years came from residents of ALFs and BHFs, with the remainder primarily from skilled nursing facilities (SNFs). As of December 31, 2025, Guardian operated 61 pharmacies, 54 of which are full-service, serving approximately 205,000 residents in approximately 8,400 LTCFs across 38 states. The company addresses challenges in ALFs and BHFs, such as residents being on various pharmacy benefit plans with distinct formularies and reimbursement processes, and ALFs often lacking staff with formal clinical training, on-site medical directors, or full-time nurses.

Guardian Pharmacy Services, Inc. (NYSE:GRDN) is a publicly traded company in the Life Sciences sector. Wiseek monitors GRDN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Guardian Pharmacy Q4 Revenue Beats Estimates, 2026 EBITDA Outlook Raised by Up to 5%
  • Guardian Pharmacy Reports Strong 2025 Results, Swings to Profitability with 17.9% Revenue Growth
  • Guardian Pharmacy Reports Strong Q4 & FY25 Results, Raises 2026 Adjusted EBITDA Guidance
  • Guardian Pharmacy Services Projects Low Double-Digit EBITDA Growth for 2026 Despite IRA Impact

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.45B
Net Income
$49.22M
Op. Cash Flow
$100.25M
Free Cash Flow
$86.84M
Gross Profit
$292.72M
Operating Income
$72.7M
Cash & Equivalents
$65.62M
Total Debt
$0
Debt / Equity
0.00×
Net Margin
3.4%
Source: 10-K · filed 2026-03-11 · accession 0001193125-26-102172
$43.09
52-week range · as of 2026-05-28 $19.17 – $41.36
Market cap
$2.73B
Volume
305.7K (0.7× avg)
3-mo avg 408.2K
Live data · 2026-06-14 06:17 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GRDN - Filings & News (Page 2)

GRDN
Mar 11, 2026, 4:41 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $33.05
Real-time Price: $43.09 info
Change: +$10.04 (+30%) info
Market Cap: $2.728B info
GRDN
Mar 11, 2026, 4:15 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $34.00
Real-time Price: $43.09 info
Change: +$9.09 (+27%) info
Market Cap: $2.728B info
GRDN
Mar 11, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.00
Real-time Price: $43.09 info
Change: +$9.09 (+27%) info
Market Cap: $2.728B info
GRDN
Jan 13, 2026, 4:41 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.26
Real-time Price: $43.09 info
Change: +$11.83 (+38%) info
Market Cap: $2.728B info